Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode [Operator Instruct ...

[Executive Summary & Business Update](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Update) This section provides an executive summary of Semler Scientific's business, product focus, and key financial highlights for Q4 and full-year 2023 [Company Profile & Product Focus](index=1&type=section&id=About%20Semler%20Scientific%2C%20Inc.) Semler Scientific develops innovative medical products for chronic diseases, featuring FDA-approved QuantaFlo® for arterial blood flow measurement, and is pursuing expanded indications and strategic investments - Semler Scientific focuses on innovative medical products and services for chronic diseases, with its flagship product **QuantaFlo®**, an **FDA-approved** patented point-of-care device, measuring arterial blood flow to aid in cardiovascular disease diagnosis[1](index=1&type=chunk)[17](index=17&type=chunk) - QuantaFlo® aids in diagnosing cardiovascular diseases like Peripheral Artery Disease (PAD), and the company is seeking new **510(k) clearance** to expand its diagnostic applications for other cardiovascular conditions[2](index=2&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk) - Semler Scientific made minority equity investments in Mellitus, SYNAPS Dx, and Monarch Medical Technologies LLC, whose product **EndoTool®** is used for inpatient glucose management[17](index=17&type=chunk) [2023 Q4 and Full Year Highlights](index=1&type=section&id=2023%20Q4%20and%20full%20year%20highlights) Semler Scientific achieved consistent year-over-year revenue and net income growth in Q4 and FY2023, driven by QuantaFlo® sales, reaching a record high cash balance - Revenue for both **Q4 and full-year 2023** achieved year-over-year growth[1](index=1&type=chunk)[10](index=10&type=chunk) - Net income for both **Q4 and full-year 2023** achieved year-over-year growth[1](index=1&type=chunk)[10](index=10&type=chunk) - Cash balance increased to **$57.3 million**, marking a record high for cash and cash equivalents[3](index=3&type=chunk)[10](index=10&type=chunk) [Detailed Financial Results](index=1&type=section&id=Detailed%20Financial%20Results) This section presents a detailed analysis of Semler Scientific's financial performance for FY2023 and Q4 2023, including income statements, balance sheets, and cash flow [FY2023 Performance](index=1&type=section&id=For%20the%20year%20ended%20December%2031%2C%202023%2C%20compared%20to%20the%20corresponding%20period%20of%202022) FY2023 saw strong financial growth for Semler Scientific, with total revenue up **20%** and net income up **44%**, primarily from variable fee software license revenue, alongside improved operating efficiency despite increased cost of revenue FY2023 Key Financial Data (Y-o-Y) | Metric | 2023 (million USD) | 2022 (million USD) | Y-o-Y Growth (%) | | :-------------------------------- | :------------------ | :------------------ | :--------- | | Revenue | $68.2 | $56.7 | 20% | | Fixed Fee Software License Revenue | $37.3 | $34.0 | 9% | | Variable Fee Software License Revenue | $29.0 | $21.3 | 36% | | Other Product Sales | $1.9 | $1.4 | 42% | | Cost of Revenue | $7.0 | $4.3 | 64% | | Total Operating Expenses | $45.9 | $39.5 | 16% | | Income Before Income Taxes | $24.1 | $17.7 | 36% | | Net Income | $20.6 | $14.3 | 44% | | Basic Earnings Per Share | $3.06 | $2.13 | 44% | | Diluted Earnings Per Share | $2.63 | $1.79 | 47% | - FY2023 cost of revenue included a **$2.5 million** write-off of prepaid software licenses for Insulin Insights, contributing to a **64%** year-over-year increase in cost of revenue[3](index=3&type=chunk)[4](index=4&type=chunk) - Operating expenses as a percentage of revenue decreased from **70%** in 2022 to **67%** in 2023[4](index=4&type=chunk) [Q4 2023 Performance](index=1&type=section&id=For%20the%20fourth%20quarter%20ended%20December%2031%2C%202023%2C%20compared%20to%20the%20corresponding%20period%20of%202022) Q4 2023 revenue grew **9%** and net income increased **31%**, driven by variable fee software licenses and other product sales, despite a **29%** decline in pre-tax income due to higher costs Q4 2023 Key Financial Data (Y-o-Y) | Metric | Q4 2023 (million USD) | Q4 2022 (million USD) | Y-o-Y Growth (%) | | :-------------------------------- | :------------------------ | :------------------------ | :--------- | | Revenue | $15.1 | $13.8 | 9% | | Fixed Fee Software License Revenue | $8.8 | $9.0 | -2% | | Variable Fee Software License Revenue | $5.8 | $4.5 | 28% | | Other Product Sales | $0.5 | $0.3 | 71% | | Cost of Revenue | $3.4 | $1.2 | 186% | | Total Operating Expenses | $12.5 | $10.2 | 23% | | Income Before Income Taxes | $2.8 | $4.0 | -29% | | Net Income | $4.2 | $3.2 | 31% | | Basic Earnings Per Share | $0.62 | $0.48 | 29% | | Diluted Earnings Per Share | $0.55 | $0.41 | 34% | - Q4 2023 cost of revenue included a **$2.5 million** write-off of prepaid software licenses for Insulin Insights, leading to a **186%** year-over-year increase in cost of revenue[5](index=5&type=chunk)[9](index=9&type=chunk) - Operating expenses as a percentage of revenue increased from **74%** in Q4 2022 to **83%** in Q4 2023[9](index=9&type=chunk) [Customer Concentration](index=2&type=section&id=Customer%20Concentration) Semler Scientific maintains significant customer concentration, with its top two clients contributing **71%** of FY2023 revenue and top three clients **80%** of Q4 2023 revenue - In FY2023, Semler Scientific's two largest customers (including affiliates) accounted for **36%** and **35%** of total revenue, respectively, totaling **71%**[5](index=5&type=chunk) - In Q4 2023, the top three customers (including affiliates) accounted for **37%**, **32%**, and **11%** of total revenue, respectively, totaling **80%**[6](index=6&type=chunk) [Statements of Income (Unaudited)](index=4&type=section&id=Statements%20of%20Income) The unaudited statements of income detail Q4 and full-year 2023 revenue, operating expenses, and net income, noting a **$2.5 million** cost of revenue write-off and a shift to income tax benefit in Q4 Statements of Income Summary (Unaudited, in thousand USD) | Metric | Q4 2023 | Q4 2022 | FY2023 | FY2022 | | :-------------------------------- | :------------- | :------------- | :--------- | :--------- | | Revenue | $15,056 | $13,794 | $68,184 | $56,686 | | Cost of Revenue | $3,384 | $1,182 | $6,984 | $4,252 | | Total Operating Expenses | $12,534 | $10,178 | $45,928 | $39,483 | | Operating Income | $2,522 | $3,616 | $22,256 | $17,203 | | Income Before Income Taxes | $2,814 | $3,956 | $24,100 | $17,692 | | Income Tax Expense (Benefit) | $(1,407) | $740 | $3,517 | $3,367 | | Net Income | $4,221 | $3,216 | $20,583 | $14,325 | | Basic Earnings Per Share | $0.62 | $0.48 | $3.06 | $2.13 | | Diluted Earnings Per Share | $0.55 | $0.41 | $2.63 | $1.79 | [Balance Sheets (Unaudited)](index=5&type=section&id=Balance%20Sheets) As of December 31, 2023, Semler Scientific's balance sheet shows significant total asset growth, driven by increased cash and equivalents, alongside reduced total liabilities and a substantial rise in stockholders' equity Balance Sheet Summary (Unaudited, in thousand USD) | Metric | December 31, 2023 | December 31, 2022 | Change | | :-------------------------------- | :------------- | :------------- | :----- | | Cash and Cash Equivalents | $57,200 | $23,014 | +$34,186 | | Short-Term Investments | $0 | $20,073 | -$20,073 | | Accounts Receivable, Net | $6,125 | $3,884 | +$2,241 | | Total Current Assets | $65,944 | $48,908 | +$17,036 | | Total Assets | $78,065 | $62,693 | +$15,372 | | Total Current Liabilities | $6,200 | $6,857 | -$657 | | Total Stockholders' Equity | $71,795 | $55,676 | +$16,119 | [Statements of Cash Flows (Unaudited)](index=6&type=section&id=Statements%20of%20Cash%20Flows) FY2023 saw strong **$21.3 million** net cash inflow from operations and a positive shift in investing activities, leading to a **$34.3 million** increase in cash and equivalents, reaching **$57.3 million** at year-end Statements of Cash Flows Summary (Unaudited, in thousand USD) | Metric | FY2023 | FY2022 | | :-------------------------------- | :--------- | :--------- | | Net Income | $20,583 | $14,325 | | Net Cash Provided by Operating Activities | $21,330 | $17,463 | | Net Cash Provided by (Used in) Investing Activities | $18,396 | $(26,835) | | Net Cash Used in Financing Activities | $(5,408) | $(4,937) | | Net Increase (Decrease) in Cash | $34,318 | $(14,309) | | Cash, Cash Equivalents, and Restricted Cash at End of Period | $57,332 | $23,014 | - Investing activities shifted from a net cash outflow of **$26.8 million** in 2022 to a net cash inflow of **$18.4 million** in 2023, primarily due to proceeds from maturities of short-term investments[16](index=16&type=chunk) - Taxes paid increased to **$4.06 million** in 2023, up from **$2.40 million** in 2022[16](index=16&type=chunk) [Corporate Information](index=2&type=section&id=Corporate%20Information) This section provides corporate information, including conference call details, forward-looking statements, and investor contact information [Conference Call Details](index=2&type=section&id=Notice%20of%20Conference%20Call) Semler Scientific held a conference call on March 5, 2024, to discuss Q4 and full-year 2023 financial results and provide business updates, with details for participation - The company held a conference call on **March 5, 2024, at 4:30 PM ET**, to discuss Q4 and full-year 2023 results and recent strategies[7](index=7&type=chunk) - Participants can join the conference call via online pre-registration or by dialing the provided domestic and international phone numbers[8](index=8&type=chunk)[11](index=11&type=chunk) - A replay of the conference call will be archived on Semler Scientific's website[11](index=11&type=chunk) [Forward-Looking Statements](index=7&type=section&id=Forward-Looking%20Statements) This section contains standard forward-looking statements, including intentions to seek new FDA 510(k) clearances for QuantaFlo®, subject to risks like reimbursement policy changes and regulatory approvals - The press release contains forward-looking statements, including explicit or implicit statements about seeking new **510(k) clearance** for **QuantaFlo®** to expand its indications for use[18](index=18&type=chunk) - These forward-looking statements are subject to various risks and uncertainties, such as whether insurance plans and customers will continue to license its cardiovascular testing products, changes in reimbursement policies, and the ability to successfully obtain **FDA expanded indication clearance**[18](index=18&type=chunk) - Semler Scientific undertakes no obligation to update or revise these statements unless required by law[18](index=18&type=chunk) [Investor Contact](index=7&type=section&id=INVESTOR%20CONTACT) Renae Cormier, Chief Financial Officer, serves as Semler Scientific's designated investor contact - Investor Contact: Renae Cormier, Chief Financial Officer, reachable at ir@semlerscientific.com[19](index=19&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ (Exact name of registrant as specified in its charter) Delaware 26-1367393 (St ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Doug Murphy-Chutorian – Chief Executive Officer Renae Cormier – Chief Financial Officer Jennifer Oliva Herrington – Chief Operating Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Herbert Semler – Semler Health Operator Good afternoon, and welcome to the Semler Scientific 2023 Third Quarter Financial Results Conference Call. All participants will be in a lis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (877) 77 ...

Financial Data and Key Metrics Changes - Total revenue in Q2 2023 was $18.6 million, an increase of 25% compared to Q2 2022, driven by continued sales of QuantaFlo for PAD testing [40] - Pre-tax net income was $7.7 million, an increase of $2.5 million or 48% year-over-year, while net income was $5.9 million, or $0.88 per basic share and $0.75 per diluted share, an increase of 44% year-over-year [43] Business Line Data and Key Metrics Changes - Fixed fee revenues were $9.6 million, an increase of 13% year-over-year, while variable fee revenues were $8.4 million, an increase of 39% year-over-year [41] - Equipment and other revenues were $600,000, an increase of 128% year-over-year, indicating strength in the fee per test market [42] Market Data and Key Metrics Changes - The two largest customers comprised 37% and 34% of quarterly revenues, highlighting reliance on major clients [43] - There is strong demand from home risk assessment customers using QuantaFlo for PAD during in-home examinations [41] Company Strategy and Development Direction - The company aims to maintain and enhance current revenue opportunities and profitability by reinvesting in emerging growth opportunities, particularly focusing on new customers for QuantaFlo [4] - A strategic plan to streamline operations and reduce employee headcount by approximately 30% by September 15, 2023, is in place to drive operational efficiency [2] Management's Comments on Operating Environment and Future Outlook - Management noted that it is difficult to predict customer reactions to pending changes in the risk model for PAD from CMS due to various factors at play in the market [17] - The company is committed to maintaining investments in research and development to stay at the forefront of innovation [5] Other Important Information - The company anticipates incurring severance costs in the range of $700,000 to $900,000, which are expected to result in a reduction in quarterly operating expenses of approximately $1.5 million to $2 million [3] - The company is exploring inorganic growth initiatives to diversify its product portfolio [11] Q&A Session Summary Question: Reaction of health plans and fee per test customers to CMS changes - Management indicated that it is too early to speculate on potential impacts to customers, but testing is currently at an increased rate [18] Question: Customer interest in heart dysfunction product and revenue expectations - Management confirmed positive feedback from initial installations of QuantaFlo HD, but noted that market uptake will take time and they are not providing specific guidance on revenue [19][20] Question: Priorities regarding downsizing and streamlining initiatives - Management explained that the focus is on automation and technology improvements, leading to a reduced need for certain staff areas, and emphasized the importance of capitalizing on emerging market opportunities [22]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State o ...

Financial Data and Key Metrics Changes - In Q1 2023, the company reported record high quarterly revenues of $18.2 million, an increase of 30% compared to Q1 2022 [40] - Pre-tax net income for Q1 2023 was $6.6 million, reflecting a 68% increase period-over-period [27] - Net income was $5 million, or $0.74 per basic share and $0.63 per fully diluted share, marking a 48% increase period-over-period [27] - Operating expenses, including cost of revenue, were $12 million, an increase of 18% period-over-period due to increased headcount and wage inflation [41] - Cash, cash equivalents, and short-term investments totaled $43 million as of March 31, 2023 [42] Business Line Data and Key Metrics Changes - Fixed fee revenues were $9.3 million, an increase of 18% period-over-period, driven by growth from both existing and new customers [26] - Variable fee revenues reached $8.6 million, representing a 46% increase period-over-period [26] - Equipment and other revenue was $340,000, an increase of 19% period-over-period, indicating strength in the fee per test market [11] Market Data and Key Metrics Changes - The diabetes market in the U.S. includes over 35 million diagnosed individuals, growing at 4% to 5% annually, with 96 million people having pre-diabetes [4] - Heart failure affects approximately 6.5 million adults in the U.S., with over 1 million hospitalizations annually and care costs exceeding $30 billion [1] Company Strategy and Development Direction - The company aims to establish QuantaFlo for PAD as a standard of care and expand its customer base to include hospitals and value-based care providers [15] - Plans to market and install Insulin Insights more broadly are in place, focusing on improving clinical outcomes and reducing total cost of care [18] - The company is also exploring investments to diversify its product pipeline, particularly in the diabetes space [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical benefits of early diagnosis of chronic diseases and the relevance of their mission to stakeholders [18] - The management team is prepared to adjust growth strategies as market conditions evolve, emphasizing the importance of their technology in reducing health inequities [33] - There are concerns regarding the impact of CMS's 2024 final rate announcement on the PAD testing business, as many customers rely on HCC payments [31] Other Important Information - Two new independent directors were appointed to the board, bringing expertise in capital allocation and strategic planning [9] - The company has $15 million remaining under the stock repurchase program [12] Q&A Session Summary Question: No questions were posed during the Q&A session - The operator indicated that there were no questions from participants and encouraged reaching out for any inquiries [49]

Financial Performance - Total revenues for the year ended December 31, 2022, were $56.7 million, an increase from $53.0 million in 2021, while net income decreased to $14.3 million from $17.2 million[29]. - The company needs to generate significant sales to maintain profitability, and any slower-than-expected sales growth could adversely affect financial performance[162]. - The company has experienced material weaknesses in its internal control over financial reporting, which could adversely affect its operations if additional weaknesses are identified in the future[185][186]. - The company does not anticipate paying any cash dividends on its capital stock in the foreseeable future, with capital appreciation being the sole source of gain for shareholders[203]. - Changes in tax regulations could materially impact the company's effective tax rates and overall financial performance[216]. Product Offerings and Market Potential - QuantaFlo, a patented and FDA-cleared product, is marketed primarily through a licensing model, with approximately 62% of customers on a fixed-fee model and 38% on a variable fee model based on usage[33]. - The estimated evaluable patient population for QuantaFlo is over 80 million patients in the United States annually, targeting those over 50 years old[55]. - The annual cost of care for heart failure exceeds $30 billion, with over one million hospitalizations per year in the United States[43]. - Approximately 21% of Type 2 diabetics in the U.S. require insulin, highlighting the market potential for Insulin Insights[50]. - The market opportunity for QuantaFlo is significant, given the under-diagnosed prevalence of cardiac and vascular diseases in the U.S.[42]. - The company is exploring additional product offerings through marketing and distribution arrangements, including potential acquisitions to expand its service offerings[62]. - The company is developing several updates and modifications to QuantaFlo in conjunction with engineering consultants to enhance product offerings[68]. - The company is exploring new sales models, including a fee-per-test model, to generate revenues from its products[155]. Customer and Revenue Concentration - The two largest customers accounted for 40.4% and 29.0% of revenues in 2022, compared to 40.8% and 28.6% in 2021[34]. - Two customers accounted for 40.4% and 29.0% of the company's revenues for the year ended December 31, 2022, indicating a significant revenue concentration risk[157]. - As of December 31, 2022, three customers represented 26.8%, 25.9%, and 16.8% of the company's accounts receivable, highlighting reliance on a limited customer base[157]. Regulatory and Compliance Issues - The FDA requires either 510(k) clearance or PMA approval for the commercial distribution of QuantaFlo and future medical devices[88]. - Compliance with FDA regulations is mandatory post-market, including reporting adverse events and conducting post-market surveillance[101]. - The company is subject to unannounced inspections by the FDA and must comply with stringent quality assurance procedures[101]. - The company’s cardiac and vascular testing product is subject to extensive FDA regulations, and any delays in obtaining necessary approvals could adversely affect market introduction[169]. Operational Challenges - The company faces challenges in gaining market acceptance for its products, which may not be viewed as attractive alternatives to existing devices[143]. - The company relies on a small number of independent suppliers for manufacturing, which poses risks of delays and disruptions that could impact operations[158]. - The ongoing COVID-19 pandemic has adversely affected the company’s business, particularly in terms of decreased test volumes[140]. - The company may incur significant costs related to replacing damaged products under its service model, which could affect profitability[156]. Employee and Organizational Structure - The company had 127 full-time employees as of December 31, 2022, representing a 2% increase from the previous year[127]. - The company expects to continue experiencing growth in the number of employees, particularly in sales, marketing, and distribution[127]. - The company had 81 sales and marketing employees as of December 31, 2022, and faces risks in managing its distribution network[154]. Financial Risks and Investments - The company has invested $2.5 million in licenses for Insulin Insights, an FDA-cleared software product for optimizing insulin dosing, with distribution under a SaaS model[36]. - The company has prepaid an aggregate of $2.5 million for software licenses related to Insulin Insights, with $2.0 million paid in April 2021 and $0.5 million in December 2022[141]. - The company wrote down $1.2 million of inventory in Q4 2021 due to inaccurate expectations regarding marketing and distribution of a product line[137]. - The company has a minority investment in NeuroDiagnostics Inc. and committed to loan up to $5.0 million to Monarch, a digital health company[141]. - The company may face significant costs due to potential product recalls or market withdrawals, which could adversely affect its business[207]. Market Competition - Competitors are beginning to market digital devices for vascular testing, indicating a growing competitive landscape[67]. - The company operates in a highly competitive medical device market, facing competition from larger firms with greater resources[215]. Stock and Shareholder Information - Approximately 47.0% of the company's common stock is beneficially owned by executive officers, directors, and significant stockholders, allowing them to substantially influence shareholder decisions[195]. - The company's stock price has been volatile, influenced by various factors, which could result in substantial losses for purchasers of its common stock[200]. - The company is classified as a "smaller reporting company," which allows it to take advantage of reduced disclosure requirements, potentially making its stock less attractive to investors[217]. - The company may experience future dilution from additional equity offerings to raise capital or pursue acquisitions[222]. Legal and Regulatory Environment - The company is subject to federal and state healthcare laws, including anti-kickback and false claims laws, which could result in substantial penalties for non-compliance[112]. - The federal Anti-Kickback Law prohibits unlawful inducements for referrals of business reimbursable under federally-funded healthcare programs[108]. - The U.S. Department of Justice has increased scrutiny of interactions between healthcare companies and providers, leading to a rise in investigations and settlements[115]. - Future legislation could impact the company's prospects and the actions of payors for healthcare treatment and services[120]. Financial Management and Cash Holdings - The company holds approximately $30.1 million in U.S. Treasury bills as of December 31, 2022, with the remainder of cash in non-interest bearing accounts[211]. - The company is taking steps to diversify its cash holdings to mitigate risks associated with financial institutions in receivership[211]. - Fluctuations in insurance costs could adversely affect the company's profitability and risk management profile[214]. - Increased costs are anticipated as a result of operating as a public company, including compliance with the Sarbanes-Oxley Act and other regulations[221].

Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2022 Results Conference Call March 21, 2023 4:30 PM ET Company Participants Douglas Murphy-Chutorian - CEO, Corporate Secretary Wayne Pan - New CEO Renae Cormier - Head, Corporate Communication and Business Strategy Andrew Weinstein - SVP, Finance & Accounting Dennis Rosenberg - Chief Marketing Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2022 Fourth Quarter and Full Yea ...